Abstract
In breast cancer cells, 17-β-estradiol (E2) upregulates the expression of insulin receptor substrate 1 (IRS-1), a molecule transmitting insulin-like growth factor-I (IGF-I) signals through the PI-3K/Akt survival pathways. The stimulation of IRS-1 by E2 has been documented on the transcriptional level. Here we studied whether the expression of estrogen receptor (ER)-α affects IRS molecules post-transcriptionally. We used ER-α-negative MDA-MB-231 breast cancer cells and MDA-MB-231 cells with re-expressed ER-α. In MDA-MB-231 cells cultured under serum-free conditions, IRS-1 and IRS-2 were degraded through the 26S proteasome and calpain pathways. Re-expression of ER-α in MDA-MB-231 cells correlated with enhanced stability of IRS molecules. This effect coincided with significantly reduced ubiquitination of IRS-1 and IRS-2, but did not involve increased IRS-1 and IRS-2 transcription. The interference of ER-α with IRS-1 and IRS-2 turnover could rely on the competition for common degradation pathways, as in MDA-MB-231/ER cells, ER-α processing was blocked by proteasome and calpain inhibitors. Notably, a fraction of the cytosolic ER-α colocalized and coprecipitated with IRS-1 and IRS-2, indicating a possible common destination for these proteins. The stabilization of IRS-1 in MDA-MB-231/ER cells was paralleled by the upregulation of the IRS-1/Akt/GSK-3 pathway and improved survival in the presence of IGF-I, whereas IRS-2 was not involved in IGF-I signaling.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aberle H, Bauer A, Stappert J, Kispert A and Kemler R . (1997). EMBO J., 16, 3797–3804.
Aguirre V and White M . (2000). Curr. Opin. Endocrin. Diab., 7, 1–7.
Araki E, Sun XJ, Haag III BL, Chuang LM, Zhang Y, Yang-Feng TL, White MF and Kahn CR . (1993). Diabetes, 42, 1041–1054.
Ashok BT, Kim E, Mittelman A and Tiwari RK . (2001). Int. J. Mol. Med., 8, 385–390.
Bartucci M, Morelli C, Mauro L, Ando' S and Surmacz E . (2001). Cancer Res., 61, 6747–6754.
Bergmann U, Funatomi H, Kornmann M, Beger HG and Korc M . (1996). Biochem. Biophys. Res. Commun., 220, 886–890.
Burks DJ and White MF . (2001). Diabetes, 50, S140–S145.
Ducluzeau PH, Perretti N, Laville M, Andreelli F, Vega N, Riou JP and Vidal H . (2001). Diabetes, 50, 1134–1142.
Dupont J, Derouet M, Simon J and Taouis M . (1999). J. Endocrinol., 162, 67–76.
Fasshauer M, Klein J, Kriauciunas KM, Ueki K, Benito M and Kahn CR . (2001). Mol. Cell. Biol., 21, 319–329.
Giovannone B, Scaldaferri ML, Federici M, Porzio O, Lauro D, Fusco A, Sbraccia P, Borboni P, Lauro R and Sesti G . (2000). Diabetes Metab. Res. Rev., 16, 434–441.
Guvakova MA and Surmacz E . (1997). Cancer Res., 57, 2606–2610.
Jackson JG, White MF and Yee D . (1998). J. Biol. Chem., 273, 9994–10003.
Jackson JG, Zhang X, Yoneda T and Yee D . (2001). Oncogene, 20, 7318–7325.
Joazeiro CAP and Hunter T . (2000). Science, 289, 2061–2062.
Kahlert S, Nuedling S, Van Eickels M, Vetter H, Meyer R and Grohe' C . (2000) J. Biol. Chem., 275, 18447–18453.
Kornmann M, Maruyama H, Bergmann U, Tangvoranuntakul P, Beger HG, White MF and Korc M . (1998). Cancer Res., 58, 4250–4254.
Lassak A, Del Valle L, Peruzzi F, Wang JY, Enam S, Croul S, Khalili K and Reiss K . (2002). J. Biol. Chem., 277, 17231–17238.
Lee AV, Gooch JL, Oesterreich S, Guler RL and Yee D . (2000). Mol. Cell. Biol., 20, 1489–1496.
Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK and Yee D . (1999). Mol. Endocrinol., 13, 787–796.
Lonard DM, Nawaz Z, Smith CL and O'Malley BW . (2000). Mol. Cell., 5, 939–948.
Mauro L, Salerno M, Panno ML, Bellizzi D, Sisci D, Miglietta A, Surmacz E and Ando' S . (2001). Biochem. Biophys. Res. Commun., 288, 685–689.
Molloy CA, May FE and Westley BR (2000). J. Biol. Chem., 275, 12565–12571.
Murayama A, Fukai F and Murachi T . (1984). J. Biochem., 95, 1697–1704.
Nawaz Z, Lonard DM, Dennis A, Smith CL and O'Malley BW . (1999). Proc. Natl. Acad. Sci. USA, 96, 1858–1862.
Pederson TM, Kramer DL and Rondinone CM (2001). Diabetes, 50, 24–31.
Powzaniuk MA, Trotta R, Loza MJ, Harth A, Iozzo RV, Eisenlohr LC, Perussia B and Calabretta B . (2001). J. Immunol., 167, 242–249.
Prisco M, Santini F, Baffa R, Liu M, Drakas R, Wu A and Baserga R . (2002). J. Biol. Chem., 277, 32078–32085.
Rice KM, Turnbow MA and Gamer CW . (1993). Biochem. Biophys. Res. Commun., 190, 961–197.
Richards GR, Klotz DM, Bush MR, Walmer DK and DiAugustine RP . (2001). Endocrinology, 142, 3842–3849.
Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K, Moelling K, Yancopoulos GD and Glass DJ . (1999). Science, 286, 1738–1740.
Rui L, Fisher TL, Thomas J and White MF . (2001). J. Biol. Chem., 276, 40362–40367.
Sachdev D and Yee D . (2001). Endocr. Relat. Cancer, 8, 197–209.
Sakoda H, Ogihara T, Anai M, Funaki M, Inukai K, Katagiri H, Fukushima Y, Onishi Y, Ono H, Fujishiro M, Kikuchi M, Oka Y and Asano T . (2000). Diabetes, 49, 1700–1708.
Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S and Surmacz E . (1999). Int. J. Cancer, 81, 299–304.
Sasaki Y, Zhang XF, Nishiyama M, Avruch J and Wands JR . (1993). J. Biol. Chem., 268, 3805–3808.
Shaw LM . (2001). Mol. Cell. Biol., 21, 5082–5093.
Shepherd PR, Withers D and Siddle K . (1998). Biochem. J., 333, 471–490.
Shiba E, Shoushin K, Fujitani M, Kambayashi J, Kawamura I, Tsujimoto S, Shimomura K, Tanji Y, Taguchi T, Kimoto Y, Izukura M and Takai S . (1996). Anticancer Res., 16, 773–778.
Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW and Liao JK . (2000). Nature, 407, 538–541.
Smith LK, Bradshaw M, Croall DE and Garner CW . (1993). Biochem. Biophys. Res. Commun., 196, 767–772.
Smith LK, Rice KM and Garner CW . (1996). Mol. Cell. Endocrinol., 30, 81–92.
Smith U, Gogg S, Johansson A, Olausson T, Rotter V and Svalstedt B . (2001). FASEB J., 15, 215–220.
Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R and Santen RJ . (2002). Mol. Endocrinol., 16, 116–127.
Spector SA, Olson ET, Gumbs AA, Friess H, Buchler MW and Seymour NE . (1999). J. Surg. Res., 83, 32–35.
Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV and Cheng JQ . (2001). Cancer Res., 61, 5985–5991.
Sun XJ, Goldberg JL, Qiao L and Mitchell JJ . (1999). Diabetes, 48, 1359–1364.
Surmacz E . (2000). J. Mammary Gland Biol. Neoplasia, 5, 95–105.
Turnbow MA, Keller SR, Rice KM and Garner CW . (1994). J. Biol. Chem., 269, 2516–2520.
Vassen L, Wegrzyn W and Klein-Hitpass L . (1999). Mol. Endocrinol., 13, 485–494.
Yenush L and White MF . (1997). BioEssays, 19, 491–500.
Zhang H, Hoff H and Sell C . (2000). J. Biol. Chem., 275, 22558–22562.
Zhang J, Ou J, Bashmakov Y, Horton JD, Brown MS and, Goldstein JL . (2001). Proc. Natl. Acad. Sci. USA, 27, 3756–3761.
Zimmermann S and Moelling K . (1999). Science, 286, 1741–1744.
Acknowledgements
This work was supported by the US Department of Defense Breast Cancer Research Program Grants DAMD17-99-1-9407 and DAMD 17-97-1-7211, and by the American–Italian Cancer Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morelli, C., Garofalo, C., Bartucci, M. et al. Estrogen receptor-α regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene 22, 4007–4016 (2003). https://doi.org/10.1038/sj.onc.1206436
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206436
Keywords
This article is cited by
-
The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer
Oncogene (2019)
-
MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells
Breast Cancer Research (2012)
-
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer
Breast Cancer Research and Treatment (2010)
-
Insulin receptor substrate 2 plays important roles in 17β-estradiol-induced bone formation
Journal of Endocrinological Investigation (2009)
-
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2
Nature Clinical Practice Oncology (2008)